BiocurePharm, Korea (BPK) Signs MOU With Symbasis GmbH to Develop CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL)
Vancouver, British Columbia–(Newsfile Corp. – January 4, 2021) – Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) (CURE or the Company) BiocurePharm, Korea (BPK), a subsidiary of Biocure Technology Inc. (CURE) is pleased to announce that BPK has entered into a MOU with Symbasis GmbH. They have expressed a common interest in developing a CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL) and wish to sign this MOU for the purpose of confirming their intention in respect to the development.
The purpose of this MOU is to establish a Joint Venture in Germany under the name „Oncocart“ for clinical trials, production and marketing in Europe, (potentially, including other regions of the world) of ROR1-based products for the CAR-T therapy the target indication of which is CLL. The MOU is intended to form the basis of discussions and negotiations between the Parties for the purpose of entering into final agreements without creating any obligation to do so. Both parties agree that this Joint Venture will enable them to bring together an extremely experienced group of experts and professionals, allowing for all phases of the development to advance more effectively.
„Oncocart“ is advised by renowned hemato-oncological experts. Among others Prof. Dr. Karl-Anton Kreuzer and Prof. Dr. Christoph Scheid are providing their in-depth knowledge for the development of CAR-T therapy. Both are consultant physicians at the University of Cologne Medical Center, which hosts the world’s largest study group for Chronic Lymphocytic Leukemia (CLL), is a leading institution for clinical CAR-T trials and serves as a National Cancer Center in Germany.
Goldberg Consulting will act as advisors for the newly formed Oncocart. Goldberg supports companies in the health and social economy sector with an interdisciplinary network of qualified exprerts. (https://www.goldberg-consult.de/en/)
Dr. Sang Mok Lee, CEO and President of Biocure and BPK, states, „This MOU is an important milestone for the Company to advance it’s entrance into the European market with its CAR T technology. With clinical trials commencing in Korea, we are confident, that with the right positive outcomes, we can expedite the process into the European market, allowing patients access to an affordable CAR T Therapy and ultimately saving more lives. We continue to work hard to make this happen as soon as possible.“